Dr Emilio Cosimo

Emilio joined RoukenBio as Scientific Director of Innovation in 2025. He holds a Ph.D. in Targeted Radiotherapy and Gene Therapy from the University of Glasgow, where his research focused on tumour-specific gene expression systems and innovative delivery methods to enhance radionuclide-based therapies for neuroblastoma.

Throughout his career, Emilio has developed a strong passion for bridging science and strategy, with a focus on translating novel research into impactful therapies that improve patient outcomes.

He brings over 18 years of experience in oncology, immuno-oncology, and advanced cell therapies, with a strong focus on translational research and drug discovery. Prior to joining RoukenBio, Emilio led the development and clinical implementation of allogeneic, cryopreserved “off-the-shelf” cell therapies and progressed next-generation CAR-T platforms targeting solid tumours. His work spans early-stage discovery, process development, IND-enabling studies, and regulatory engagement with agencies including the FDA and MHRA.

At RoukenBio, Emilio is responsible for driving the development of novel solutions, cutting-edge platforms, and bespoke service offerings that help clients accelerate the path from discovery to clinical application.